Glucagon-Like Peptide-1 Protects Against Atrial Fibrillation and Atrial Remodeling in Type 2 Diabetic Mice

Atrial fibrillation (AF) is highly prevalent in type 2 diabetes where it increases morbidity and mortality. Glucagon-like peptide (GLP)-1 receptor agonists are used in the treatment of type 2 diabetes (T2DM), but their effects on AF in T2DM are poorly understood. The present study demonstrates type...

Descripción completa

Detalles Bibliográficos
Autores principales: Bohne, Loryn J., Jansen, Hailey J., Dorey, Tristan W., Daniel, Irene M., Jamieson, K. Lockhart, Belke, Darrell D., McRae, Megan D., Rose, Robert A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Original Research - Preclinical
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10504404/
https://www.ncbi.nlm.nih.gov/pubmed/37719430
http://dx.doi.org/10.1016/j.jacbts.2023.01.005
_version_ 1785106718183653376
author Bohne, Loryn J.
Jansen, Hailey J.
Dorey, Tristan W.
Daniel, Irene M.
Jamieson, K. Lockhart
Belke, Darrell D.
McRae, Megan D.
Rose, Robert A.
author_facet Bohne, Loryn J.
Jansen, Hailey J.
Dorey, Tristan W.
Daniel, Irene M.
Jamieson, K. Lockhart
Belke, Darrell D.
McRae, Megan D.
Rose, Robert A.
author_sort Bohne, Loryn J.
collection PubMed
description Atrial fibrillation (AF) is highly prevalent in type 2 diabetes where it increases morbidity and mortality. Glucagon-like peptide (GLP)-1 receptor agonists are used in the treatment of type 2 diabetes (T2DM), but their effects on AF in T2DM are poorly understood. The present study demonstrates type 2 diabetic db/db mice are highly susceptible to AF in association with atrial electrical and structural remodeling. GLP-1, as well as the long-acting GLP-1 analogue liraglutide, reduced AF and prevented atrial remodeling in db/db mice. These data suggest that GLP-1 and related analogues could protect against AF in patients with T2DM.
format Online
Article
Text
id pubmed-10504404
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-105044042023-09-17 Glucagon-Like Peptide-1 Protects Against Atrial Fibrillation and Atrial Remodeling in Type 2 Diabetic Mice Bohne, Loryn J. Jansen, Hailey J. Dorey, Tristan W. Daniel, Irene M. Jamieson, K. Lockhart Belke, Darrell D. McRae, Megan D. Rose, Robert A. JACC Basic Transl Sci Original Research - Preclinical Atrial fibrillation (AF) is highly prevalent in type 2 diabetes where it increases morbidity and mortality. Glucagon-like peptide (GLP)-1 receptor agonists are used in the treatment of type 2 diabetes (T2DM), but their effects on AF in T2DM are poorly understood. The present study demonstrates type 2 diabetic db/db mice are highly susceptible to AF in association with atrial electrical and structural remodeling. GLP-1, as well as the long-acting GLP-1 analogue liraglutide, reduced AF and prevented atrial remodeling in db/db mice. These data suggest that GLP-1 and related analogues could protect against AF in patients with T2DM. Elsevier 2023-03-15 /pmc/articles/PMC10504404/ /pubmed/37719430 http://dx.doi.org/10.1016/j.jacbts.2023.01.005 Text en © 2023 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Original Research - Preclinical
Bohne, Loryn J.
Jansen, Hailey J.
Dorey, Tristan W.
Daniel, Irene M.
Jamieson, K. Lockhart
Belke, Darrell D.
McRae, Megan D.
Rose, Robert A.
Glucagon-Like Peptide-1 Protects Against Atrial Fibrillation and Atrial Remodeling in Type 2 Diabetic Mice
title Glucagon-Like Peptide-1 Protects Against Atrial Fibrillation and Atrial Remodeling in Type 2 Diabetic Mice
title_full Glucagon-Like Peptide-1 Protects Against Atrial Fibrillation and Atrial Remodeling in Type 2 Diabetic Mice
title_fullStr Glucagon-Like Peptide-1 Protects Against Atrial Fibrillation and Atrial Remodeling in Type 2 Diabetic Mice
title_full_unstemmed Glucagon-Like Peptide-1 Protects Against Atrial Fibrillation and Atrial Remodeling in Type 2 Diabetic Mice
title_short Glucagon-Like Peptide-1 Protects Against Atrial Fibrillation and Atrial Remodeling in Type 2 Diabetic Mice
title_sort glucagon-like peptide-1 protects against atrial fibrillation and atrial remodeling in type 2 diabetic mice
topic Original Research - Preclinical
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10504404/
https://www.ncbi.nlm.nih.gov/pubmed/37719430
http://dx.doi.org/10.1016/j.jacbts.2023.01.005
work_keys_str_mv AT bohnelorynj glucagonlikepeptide1protectsagainstatrialfibrillationandatrialremodelingintype2diabeticmice
AT jansenhaileyj glucagonlikepeptide1protectsagainstatrialfibrillationandatrialremodelingintype2diabeticmice
AT doreytristanw glucagonlikepeptide1protectsagainstatrialfibrillationandatrialremodelingintype2diabeticmice
AT danielirenem glucagonlikepeptide1protectsagainstatrialfibrillationandatrialremodelingintype2diabeticmice
AT jamiesonklockhart glucagonlikepeptide1protectsagainstatrialfibrillationandatrialremodelingintype2diabeticmice
AT belkedarrelld glucagonlikepeptide1protectsagainstatrialfibrillationandatrialremodelingintype2diabeticmice
AT mcraemegand glucagonlikepeptide1protectsagainstatrialfibrillationandatrialremodelingintype2diabeticmice
AT roseroberta glucagonlikepeptide1protectsagainstatrialfibrillationandatrialremodelingintype2diabeticmice

Ejemplares similares